tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Immunic announces vidofludimus calcium trial data
PremiumThe FlyImmunic announces vidofludimus calcium trial data
3M ago
Immunic completes enrollment for both ENSURE trials
Premium
The Fly
Immunic completes enrollment for both ENSURE trials
3M ago
Immunic Approves Equity Plan Amendment at Annual Meeting
Premium
Company Announcements
Immunic Approves Equity Plan Amendment at Annual Meeting
3M ago
Immunic announces offering of warrants to purchase common stock
PremiumThe FlyImmunic announces offering of warrants to purchase common stock
4M ago
Immunic price target lowered to $5 from $6 at B. Riley
Premium
The Fly
Immunic price target lowered to $5 from $6 at B. Riley
4M ago
Buy Rating Affirmed for Immunic’s Vidofludimus Calcium Due to Promising Phase 2 Results and Strong MS Treatment Potential
Premium
Ratings
Buy Rating Affirmed for Immunic’s Vidofludimus Calcium Due to Promising Phase 2 Results and Strong MS Treatment Potential
4M ago
Immunic price target raised to $22 from $19 at Brookline
PremiumThe FlyImmunic price target raised to $22 from $19 at Brookline
5M ago
Immunic’s Vidofludimus Calcium Shows Promise in Treating Progressive MS: Analyst Upgrades to Buy
Premium
Ratings
Immunic’s Vidofludimus Calcium Shows Promise in Treating Progressive MS: Analyst Upgrades to Buy
5M ago
Immunic’s vidofludimus calcium shows positive results in Phase 2 PMS trial
Premium
The Fly
Immunic’s vidofludimus calcium shows positive results in Phase 2 PMS trial
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100